Scientist conducting AI drug discovery and biological aging research in a modern laboratory
| |

The Longevity Toolkit Takes Shape: AI Drug Discovery, Biological Age Clocks, and Microbiome Science Converge

A generative AI-designed drug has delivered clinical proof in a Phase IIa trial, while new biological age clocks and microbiome science are completing the precision longevity toolkit. Here is what…

Scientist examining samples in a modern research laboratory representing longevity and epigenetic reprogramming breakthroughs
| |

Epigenetic Reprogramming Goes Human: Three Breakthroughs Signal a Turning Point for Longevity Science

The first human trial of partial epigenetic reprogramming has launched, an AI platform published in Cell is accelerating longevity drug discovery, and a landmark NEJM trial proves cardiovascular primary prevention…

Scientist examining DNA and cellular reprogramming data in a longevity research laboratory
| |

Longevity’s Reprogramming Moment: AI Drugs, Cellular Epigenetics, and Gut Microbiome Science Converge

Three landmark breakthroughs in longevity reprogramming research 2026 are reshaping what science knows about human aging. An AI-designed drug proves itself in clinical trials, the first human epigenetic reprogramming trial…

Healthcare Discovery longevity medicine landmark week showing heart disease prevention AI-discovered cures and Alzheimer's reversal research
| |

Heart Disease at 30, AI-Discovered Cures, and Reversed Alzheimer’s: Longevity Medicine’s Landmark Week

Three landmark developments are rewriting the rules of longevity medicine: cardiovascular prevention now starting at age 30, an AI platform published in Cell discovering treatments for liver cancer and pulmonary…

Healthcare Discovery longevity breakthroughs 2026 showing gut bacteria epigenetic reprogramming and AI converging
| |

Longevity Breakthroughs 2026: Gut Bacteria, Epigenetic Reprogramming, and AI Converge at a Historic Inflection Point

Three landmark discoveries in early 2026 reveal how gut bacteria drive brain aging, epigenetic reprogramming enters its first human trial, and AI accelerates longevity science toward escape velocity.

Gut microbiome, NAD+ energy pathways, and AI therapeutics converging on biological aging reversal
| |

Gut Bacteria, NAD+, and AI Therapeutics: Three Breakthroughs Point Toward Reversing Biological Aging

New research from Stanford, Oslo, and Insilico Medicine reveals how gut bacteria, NAD+ depletion, and AI drug discovery are converging on reversing biological aging. Three breakthroughs, one accelerating frontier.

Gut-brain signaling, epigenetic genome reset, and AI drug discovery converging on aging reversal
| |

From the Gut to the Genome: Three Converging Breakthroughs Redefine Aging Reversal in 2026

A landmark Nature study, the first FDA-cleared epigenetic reprogramming trial, and a next-generation AI drug discovery model converged in early 2026, signaling that aging reversal science has crossed into clinical…